Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Oak Street Health, Inc. ("Oak Street Health") announced today the appointment of Brian Clem as Chief Operating Officer of the Company. Mr Clem's appointment in this role will be effective as of January 1, 2022. In this new role, Mr. Clem will continue to report to the Company's Chief Executive Officer. Mr. Clem has served as the President of Oak Street Health since 2019, having joined the company in 2015 as a Regional Vice President and subsequently being promoted to Divisional President. Prior to joining Oak Street Health, Brian led the Medicare Advantage business from 2013 until 2015 at IU Health Plans, which is part of the Indiana University Health system. Prior to 2013, Brian served in leadership roles at Eli Lilly & Co., a global pharmaceutical company, beginning in 2004. Brian received an M.B.A. from Stanford University's Graduate School of Business and a B.A. in Economics from Wabash College.

Mr. Clem succeeds Geoffrey Price who will become, as of January 1, 2022, the Company's Chief Innovation Officer. Mr. Price will continue to serve on the Company's Board of Directors. Mr. Price has served as the Company's Chief Operating Officer and a member of the Company's Board since he co-founded the Company in 2012. Prior to co-founding Oak Street Health, Mr. Price was a Project Leader from 2012 until 2013 and a Consultant from 2010 to 2012 at Boston Consulting Group. Mr. Price received an M.B.A. from Harvard Business School and a B.S. in Engineering from the University of Illinois. Mr. Price will continue to report, in this new role, to the Company's Chief Executive Officer.

Any material changes or amendments to Mr. Clem's or Mr. Price's compensation arrangements in connection with these appointments have not yet been determined. In accordance with Instruction 2 to Item 5.02 of Form 8-K, the Company intends to file an amendment to this Current Report on Form 8-K if and when such information is available.

Item 7.01 Regulation FD Disclosure

On December 29, 2021, the Company issued a press release announcing these appointments as well as certain other leadership appointments. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information reported in this Item 7.01 (including Exhibit 99.1) is furnished to and not "filed" with the Securities and Exchange Commission for the purposes of the Securities Exchange Act of 1934, as amended, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shell be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits



Exhibit   Description
99.1        Press Release Dated December 29  , 2021
104       Cover Page Interactive Data File (embedded within the Inline XBRL document)




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses